학술논문
Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico
Document Type
article
Author
Juan Carlos Ivancevich; Victoria Cardona; Désirée Larenas-Linnemann; Joaquim Mullol; Hugo Neffen; Mario Zernotti; Estrella Asayag; Ariel Eduardo Blua; R. Maximiliano Gómez; Edgardo Jares; Jorge Máspero; Josep M. Anto; Toni Dedeu; Mónica Rodríguez-González; Yunuen Rocío Huerta-Villalobos; José Miguel Fuentes-Pérez; Eréndira Rodríguez-Zagal; Antonio Valero; Joan Bartra; Isam Alobid; José Antonio Castillo-Vizuete; Teresa Dordal; Rafael Hijano; César Picado; Joaquín Sastre; Martín Bedolla-Barajas; María Teresa Burguete-Cabañas; María del Carmen Costa-Domínguez; Margarita Domínguez-Silva; Jesús Guillermo Espinoza-Contreras; José Luis Gálvez-Romero; Cecilia Yvonne García-Cobas; María de la Luz Hortensia García-Cruz; Luiana Hernández-Velázquez; Jorge A. Luna-Pech; Juan José Matta; María Dolores Mogica-Martínez; Daniela Rivero-Yeverino; Lucy Tania Ruiz; Blanca E. Del Río-Navarro; Javier Gómez-Vera; Alejandra Macías-Weinmann; Ionna Agache; Ignacio Ansotegui; Claus Bachert; Anna Bedbrook; Giorgio Walter Canonica; Thomas B. Casale; Álvaro Cruz; Wytske Fokkens; Peter Hellings; Bolesław Samolinski; Jean Bousquet
Source
Revista Alergia México, Vol 66, Iss 4, Pp 409-425 (2019)
Subject
Language
English
Spanish; Castilian
Spanish; Castilian
ISSN
0002-5151
2448-9190
2448-9190
Abstract
The health and economic impact of allergic diseases are increasing rapidly, and changes in management strategies are required. Its influence reduces the capacity of work and school performance by at least a third. The ICPs of the airways (integrated care pathways for respiratory diseases) are structured multidisciplinary healthcare plans, promoting the recommendations of the guidelines in local protocols and their application to clinical practice. This document presents an executive summary for Argentina, Mexico, and Spain. Next-generation ARIA guidelines are being developed for the pharmacological treatment of allergic rhinitis (AR), using the GRADE-based guidelines for AR, tested with real-life evidence provided by mobile technology with visual analogue scales. It is concluded that in the AR treatment, H1-antihistamines are less effective than intranasal corticosteroids (INCS), in severe AR the INCS represent the first line of treatment, and intranasal combination INCS + anti-H1 is more effective than monotherapy. However, according to the MASK real-life observational study, patients have poor adherence to treatment and often self-medicate, according to their needs.